2023 Gateway Award Recipients
Please join us in Congratulating the newly funded 2023 NIH NIDDK HIRN Gateway Investigators. This initiative is designed to support a robust pipeline of innovative projects and talented new investigators in T1D research.
NIH Sponsored Webinars
- NIDDK and NIDDK Central Repository are hosting a data-centric challenge with the goal of generating an “AI-ready” dataset that can be used for future data challenges and to produce methods that can be used to enhance the AI-readiness of NIDDK data. Participants will enhance data on T1D available through the NIDDK Central Repository from the TEDDY and TrialNet studies.
Phase 1 open until November 30, 2023.
Challenge runs from December 1, 2023 – January 10, 2024.
NIH NIDDK Funding Opportunities
- HIRN Consortium on Modeling Autoimmune Diabetes (HIRN-CMAD)(RFA-DK-23-004)
– Application due date: March 20, 2024
– Earliest grant start date: December 2024
- Cardiovascular Repository Type 1 Diabetes (CARE-T1D) Consortium (RFAK-DK-20-001)
– Informational webinar scheduled for Monday, Nov 27th, at 11 am ET
HIRN 2023 Trainee PRESENTATION Award Recipients
Congratulations to the following three trainees who received an award at the 2023 Annual Investigator Meeting for their oral presentation. Award recipients were selected solely based on evaluations by HIRN members on their presentations at the Annual Investigator Meeting.
HIRN 2023 Trainee POSTER Award Recipients
Congratulations to the following seven trainees who received an award at the 2023 Annual Investigator Meeting for their scientific poster. Award recipients were selected solely based on evaluations by HIRN members on their presentations at the Annual Investigator Meeting.
Recent HIRN Publication: Humanized Mouse Model of Fibrosis
Biomedical devices comprise a major component of modern medicine. However, immune mediated fibrosis and rejection can limit their function over time. Although mouse models of fibrosis such as the immunocompetent C57BL/6 strain can generate robust fibrotic responses to implanted devices, murine and human immune systems can differ greatly and results in mice do not always translate to humans. The fibrotic response observed in non-human primates resembles that observed in humans, but this model carries with it financial and ethical concerns. Doloff et al have now developed a small animal model of fibrosis using human immune system engrafted immunodeficient mice, i.e., “humanized mice”. This small animal model recapitulates the cellular and molecular fibrotic response observed in humans. These humanized mice can be used to investigate the mechanisms of the human fibrotic response and approaches to ameliorate the response. Moreover, this model can be used to test human specific therapies that cannot be tested in immunocompetent mice.
Year 5 & Year 6 Executive Summary Report
The HIRN Year 5 & Year 6 Executive Summary Report is now available online! The report reflects significant HIRN breakthroughs, developments and advancements across the entire network. This 2-year report reflects activity from October 2018 through September 2020.
Cover Image: Dan Huh, Univ. Pennsylvania, CHIB Stanger UG3. A cross-sectional view of a vascularized three-dimensional biomimetic device visualized by scanning electron microscopy. A micro-capillary is seen in cross-section along with a functional pericyte (upper right) and surrounding matrix.
HUMAN ISLET RESEARCH NETWORK MISSION
To better understand how human beta cells are lost in Type 1 Diabetes and to find innovative strategies to protect or replace functional beta cell mass in diabetic patients.
Congratulations to the November 2023 Recipients of the NIH NIDDK New Investigator Gateway Awards Congratulations to these three investigators on joining HIRN via the NIH NIDDK Gateway Award Initiative. This…Read More
The following trainees are recipients of the HIRN 2023 Annual Investigator Meeting! Award recipients were selected solely based on evaluations by HIRN members on their presentations (oral or poster) at…Read More
HIRN Webinar: “Synthetic Biology and Type 1 Diabetes: New Approaches to Protect and Construct Islets”
Thursday, August 24, 2023 (1:00 pm Eastern / 10:00 am Pacific) Register HERE Topics discussed: Immune destruction of islets in T1D requires therapeutic strategies to protect and/or replace islets Expanding…Read More
Independent Research Initiatives
CBDS is using human pancreatic tissues to discover mechanisms of cellular stress or dysfunction that may contribute to the development of autoimmunity in at-risk individuals, to identify specific biomarkers of the asymptomatic phase of T1D, and to develop innovative strategies to stop beta cell destruction early in the disease process.
CHIB is combining advances in beta cell biology and stem cell biology with tissue engineering technologies to develop microdevices that support functional human islets.
The CMAI is developing innovative approaches to model basic aspects of human T1D immunobiology using novel in vivo and in vitro platforms.
CTAR is investigating methods to increase or maintain functional beta cell mass in T1D through targeted manipulation of islet plasticity or engineered protection of beta cells from immune-mediated destruction.
The Human Pancreas Analysis Consortium (HPAC) is investigating the physical and functional organization of the human islet tissue environment, the cell-cell relationships within the pancreatic tissue ecosystem, and the contributions of non-endocrine components (acinar, ductal, vascular, perivascular, neuronal, lymphatic, immune) to islet cell function and dysfunction.
Opportunity Pool Projects
The Human Islet Research Network (HIRN) was established In 2014 to help organize and support collaborative research related to the loss of functional beta cell mass in Type 1 Diabetes (T1D). The project consists of five independent research initiatives.